DANIEL HAMSTRA to Treatment Outcome
This is a "connection" page, showing publications DANIEL HAMSTRA has written about Treatment Outcome.
Connection Strength
0.529
-
High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir =0.2 to Select Men for Short-term Hormonal Therapy. Am J Clin Oncol. 2017 Aug; 40(4):348-352.
Score: 0.048
-
Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of?a?Phase III Trial. Int J Radiat Oncol Biol Phys. 2017 04 01; 97(5):976-985.
Score: 0.046
-
Time to Nadir PSA: Of Popes and PSA--The Immortality Bias. Am J Clin Oncol. 2015 Oct; 38(5):465-71.
Score: 0.042
-
Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol. 2015 Aug; 38(4):367-72.
Score: 0.042
-
Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar 15; 121(6):844-52.
Score: 0.040
-
Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer. 2014 Apr 01; 120(7):1076-82.
Score: 0.037
-
Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2013 May 01; 86(1):64-71.
Score: 0.035
-
Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1293-301.
Score: 0.031
-
Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer. Clin Cancer Res. 2010 May 01; 16(9):2666-76.
Score: 0.029
-
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008 Jul 10; 26(20):3387-94.
Score: 0.025
-
Primary radiotherapy for childhood ependymoma? Lancet Oncol. 2007 Sep; 8(9):758-9; author reply 760-1.
Score: 0.024
-
Stereotactic Body Radiation Therapy vs Surgery for Early-Stage Non-Small Cell Lung Cancer: Does the Dealer Influence the Choice? Ann Thorac Surg. 2023 02; 115(2):354-355.
Score: 0.017
-
Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018 06 14; 4(6):e180039.
Score: 0.013
-
Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU Int. 2018 01; 121(1):61-68.
Score: 0.012
-
Brainstem Low-Grade Gliomas in Children-Excellent Outcomes With Multimodality Therapy. J Child Neurol. 2017 02; 32(2):194-203.
Score: 0.011
-
Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. J Urol. 2017 02; 197(2):376-384.
Score: 0.011
-
Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. Prostate Cancer Prostatic Dis. 2016 09; 19(3):292-7.
Score: 0.011
-
Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy. Am J Clin Oncol. 2016 Apr; 39(2):181-8.
Score: 0.011
-
Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol. 2015 Mar; 67(3):460-7.
Score: 0.010
-
Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancer. Med Dosim. 2012; 37(3):240-4.
Score: 0.008
-
Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):940-6.
Score: 0.008
-
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010 May 01; 28(13):2293-9.
Score: 0.007
-
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med. 2009 May; 15(5):572-6.
Score: 0.007
-
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther. 2000 Jun; 7(12):1005-10.
Score: 0.004